Sagility Limited (NSE: SAGILITY) has announced its Q2 FY27 results, showcasing robust performance with 11.9% year-over-year constant currency organic growth. The company won $40.2M in ACV from 31 existing clients and 1 new logo, indicating increasing traction in larger deals.

Financial Highlights

The financial performance highlights include a revenue of ₹ 20,321 Million, an Adjusted EBITDA of ₹ 5,353 Million, and an Adjusted PAT of ₹ 3,254 Million. The company’s margin stood at 26.3% for Adjusted EBITDA and 16.0% for Adjusted PAT.

Growth and Expansion

Sagility’s growth is further supported by its acquisition of Chirok Health LLC, which adds specialized CDI and coding capabilities, extending its end-to-end RCM offering and unlocking new growth opportunities. The acquisition is expected to broaden Sagility’s provider footprint and deliver greater client value.

As a result, Sagility continues to strengthen its market position and drive forward-looking growth prospects.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of SAGILITY LIMITED

SAGILITY LIMITED belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

SAGILITY rises 8.5% over three months, with buying pressure holding steady. The PEG of 0.25 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.5% and profits at 86.1% CAGR. That is strong double-digit growth on both counts. The stock holds at 43% of its 52-week range with RSI at 56. In other words, neither side has a clear edge right now. Revenue grows at 19.5% and profits at 86.1%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of SAGILITY LIMITED.

Indegene Limited (INDGN) has been honored with Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for its outstanding achievements in AI-powered pharma commercialization. This recognition underscores Indegene’s leadership in transforming pharmaceutical commercialization workflows through domain-led AI, knowledge orchestration, and integrated execution.

Recognition Highlights

Frost & Sullivan commends Indegene for its ability to align its AI strategy with the evolving needs of the pharmaceutical industry while executing at scale across commercial, medical, regulatory, safety, analytics, content, and field engagement workflows. The recognition highlights Indegene’s leadership in modernizing complex commercialization processes through domain expertise, technology, data, and execution support.

Innovative Approach

Indegene’s Pharma Operating System (OS) connects business decisions, workflow execution, and intelligence across the enterprise, helping pharmaceutical organizations replace fragmented processes with integrated and adaptive operating models. Its Cortex life sciences-native reasoning engine enables subject matter experts to codify specialized knowledge, creating validated knowledge graphs and guiding AI-enabled workflows.

Forward-Looking Strategy

The company’s commitment to customer experience strengthens its market position by connecting strategy, data, content, execution, and measurable outcomes. Indegene’s platform-agnostic approach allows customers to work in existing technology environments, reducing adoption friction while protecting existing technology investments. This recognition reinforces Indegene’s belief in the next wave of value creation through connecting intelligence, decisions, and execution across the enterprise.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Indegene gains 17.1% over three months and trades near its 52-week highs. The PEG of 2.45 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 86% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 17.1% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.

Indegene Limited (INDGN) held its most influential Digital Summit 2026, signaling its growing influence in AI and enterprise transformation. The summit, held at the National Constitution Center in Philadelphia, attracted 120+ senior pharma leaders, with 50% decision makers and 70% Directors+. The event featured 4 keynotes, 8 panels, and presentations from industry leaders in commercial, medical, digital, data, and technology sectors.

Establishing Leadership in AI-Native Pharma Enablement

Indegene’s AI and platform capabilities emerged as one of the strongest themes of the summit. With 8 sessions exploring AI’s impact and performance from industry, leader, and capability perspectives, the summit offered a direct view into Indegene’s capabilities. The event reinforced the shift from AI experimentation to enterprise transformation.

A Venue Symbolizing Leadership and Enduring Ideas

The National Constitution Center, Philadelphia, symbolized leadership, transformation, and the future of life sciences. The ‘Freedom Rising Show’ and other experience zones delivered a premium executive experience, enabling deeper engagement with existing and prospective clients. The venue strengthened executive engagement across the U.S. life sciences ecosystem.

Future-Ready Healthcare and Strategic Positioning

IDS 2026 signaled a shift towards future-ready healthcare, with Indegene emerging as a strategic partner, AI innovator, and industry convenor. The event highlighted the importance of reimagined operating models, AI-mediated discovery, and agile organizations combining human expertise, AI intelligence, and continuous learning.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the Healthcare › Health Information Services sector. Here’s a quick read on where the business and the stock stand today.

Indegene gains 21.7% over three months and trades near its 52-week highs. The PEG of 2.46 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 21.7% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.